Form: S-8

Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

January 11, 2024

Documents

Exhibit 107
Calculation of Filing Fee Table
 
FORM S-8
(Form Type)
 
Ocuphire Pharma, Inc.
(Exact Name of Registrant as Specified in its Charter)

Newly Registered Securities

   
Security
Type
  
Security Class Title
  
Fee
Calculation
Rule
  
Amount
Registered
(1)
  
Proposed
Maximum
Offering Price
Per Unit
  
Maximum
 Aggregate Offering Price (2)
  
Fee Rate
  
Amount of
Registration
Fee
Fees to be Paid
                                
   
Equity
  
Common Stock,  par value $0.0001 per share, to be issued under the  Ocuphire Pharma, Inc. 2020  Equity Incentive Plan
 
Other (2)
  
1,198,875 (3)
  
$3.055 (2)
      
$0.0001476
    
Total Offering Amounts
                      
$3,662,563.13
      
$540.59
Total Fees Previously Paid
                              
$0.00
Total Fee Offsets
                              
$0.00
Net Fee Due
                              
$540.59

(1)
Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended, (the “Securities Act”), this Registration Statement shall also cover any additional shares of Ocuphira Pharma, Inc. (the “Registrant”) common stock that become issuable under the Registrant’s 2020 Equity Incentive Plan (the “2020 Plan”) set forth herein by reason of any stock dividend, stock split, reclassification, recapitalization, spin-off or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Registrant’s common stock, as applicable.
(2)
Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act. The offering price per share and aggregate offering price are based on the average of the high and low prices of the Registrant’s common stock as reported on the Nasdaq Capital Market on January 5, 2024.
(3)
Represents 1,198,875 additional shares of Common Stock available for issuance as a result of the annual evergreen increase on January 1, 2024 under the 2020 Plan.